From: The Hippo pathway in disease and therapy: cancer and beyond
Tissue | Protein | Model | Pathology | References |
---|---|---|---|---|
Liver | MST1/2 | MST1/2 mutant conditional mouse | Hepatomegaly | |
Heart | MST1 | Mouse model of Arrhythmogenic Cardiomyopathy and human samples | Arrhythmogenic Cardiomyopathy | [47] |
Neonatal rat ventricular myocytes | Heart failure, ischemic heart disease, dilated cardiomyopathy and cardiomyocyte apoptosis | |||
Dominant negative MST1 mice and MST1 -/- mice | Cardiac dysfunction | [51] | ||
Muscle | MST1 | MST1 deficient mice | Neurogenic muscle atrophy | [52] |
Brain | MST1 | Mouse model of Amyotrophic Lateral Sclerosis | Amyotrophic lateral sclerosis (ALS) | [53] |
Pancreas | MST1/2 | MST1/2 mutant conditional mouse | Reduction of pancreatic mass, exocrine pancreas disorganization and pancreatitis-like autodigestion | |
Thymus | MST1 | MST1 deficient patients or with homozygous mutations | Immunodeficiency, T and B cells lymphopenia | |
MST1 deficient mice | Defective lymphocyte trafficking and thymocyte egress. Autoimmune-like disorders. Impaired development and function of regulatory T cells. Low numbers of mature naïve T cells. | |||
MST1/2 | MST1 and MST2 deficient mice | Autoimmune disease (skin lesions around the eyes, lymphocytes infiltration, colitis) | ||
Lung | MST1/2 | MST1/2 mutant conditional mouse | Respiratory distress syndrome | [62] |
MST1 | Rat model of Hypoxic pulmonary vascular remodelling | Pulmonary arterial hypertension | [63] |